KRAS^G12C inhibition using MRTX1257: a novel radio-sensitizing partner.

ABSTRACT:

Background

KRAS activating mutations are considered the most frequent oncogenic drivers and are correlated with radio-resistance in multiple cancers including non-small cell lung cancer (NSCLC) and colorectal cancer. Although KRAS was considered undruggable until recently, several KRAS inhibitors have recently reached clinical development. Among them, MRTX849 (Mirati Therapeutics) showed encouraging clinical outcomes for the treatment of selected patients with KRAS^G12C mutated NSCLC and colorectal cancers. In this work, we explore the ability of MRTX1257, a KRAS^G12C inhibitor analogous to MRTX849, to radio-sensitize KRAS^G12C+/+ mutated cell lines and tumors.

Methods

Both in vitro and in vivo models of radiotherapy (RT) in association with MRT

SUBMITTER: Laurent PA 

PROVIDER: S-EPMC10619254 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature